OFW Law’s attorneys are an important resource for other law firms, investment bankers, venture capitalists, accountants, and companies seeking licensing investment, private placement or public offerings in matters requiring expertise in FDA drug, biological product, medical device and controlled substance law and regulation. Our attorneys are frequently retained to assist with due diligence evaluations of FDA-regulated companies and to provide advice on contractual language and representations and warranties for transactions involving drug, biologic, and controlled substance firms. We have advised companies and venture capital firms regarding regulatory environments surrounding drugs and biologics of concern, and have counseled companies concerning due diligence in the financing and acquisition of DEA-regulated entities.
For more information about our services, contact OFW Law’s Washington D.C. offices by telephone at (202) 789-1212 or complete our online contact form. We look forward to working with you.